The Trp53 Knockout C57BL/6 MSC Cell Line is a CRISPR/Cas9-edited knockout cell line derived from C57BL/6 mouse mesenchymal stem cells (MSCs) with targeted disruption of the Trp53 gene, which encodes the p53 tumor suppressor. Through CRISPR/Cas9-mediated gene disruption, this cell line provides a stable loss-of-function model, eliminating the need for transient gene silencing methods and ensuring reproducibility. It serves as a versatile platform for studying p53-dependent processes including cell cycle regulation, apoptosis, and senescence in cancer biology and stem cell research applications.
The parental C57BL/6 MSC line originates from the C57BL/6 inbred mouse strain, a widely used genetic background in immunological and cancer research. Mesenchymal stem cells are multipotent stromal cells capable of differentiating into osteogenic, adipogenic, and chondrogenic lineages, and they play essential roles in tissue repair, immunomodulation, and hematopoietic support. This cell line maintains key MSC characteristics, including surface marker expression and differentiation potential, providing a physiologically relevant system to study how p53 inactivation influences stem cell function and disease pathogenesis.
The Trp53 gene encodes the transcription factor p53, which orchestrates cellular responses to genotoxic stress. Upon DNA damage, upstream kinases ATM, ATR, CHK1, and CHK2 phosphorylate and activate p53, leading to transcriptional induction of target genes such as CDKN1A (p21) for cell cycle arrest and BAX, PUMA (BBC3), and NOXA (PMAIP1) for apoptosis. The E3 ubiquitin ligase MDM2 negatively regulates p53 by promoting its degradation, while cofactors including p300/CBP and ASPP1/2 fine-tune p53 activity. p53 also interacts with MDM4 and 53BP1, integrating signals that govern senescence and DNA repair decisions.
In mesenchymal stem cells, p53 is critical for maintaining genomic integrity and regulating self-renewal, lineage commitment, and senescence. Trp53 knockout in C57BL/6 MSCs enables dissection of p53’s role in stem cell biology, including how loss of p53 contributes to cancer stem cell phenotypes and impaired differentiation. This model also facilitates studies on p53-driven senescence, relevant to aging-related mesenchymal dysfunction and associated pathologies such as neurodegeneration. It thus provides a valuable system for investigating the intersection of p53 signaling with tissue homeostasis and disease.
This Trp53 knockout cell line supports a broad range of experimental applications, including investigations of tumor suppression, DNA damage response, drug-induced apoptosis, and cellular senescence. Researchers can employ western blotting and RT-qPCR to analyze p53 target gene expression, flow cytometry for cell cycle and apoptosis profiling, colony formation assays to assess clonogenic survival, and differentiation assays to evaluate MSC lineage commitment. Additional techniques such as senescence-associated ??-galactosidase staining and ??-H2AX immunofluorescence enable detailed characterization of senescence and DNA double-strand breaks. The model is applicable to studies of Li-Fraumeni syndrome, cancer drug sensitivity screening, and neurodegenerative disease mechanisms. For further technical information or to discuss specific research applications, please contact Ascent Research.
Case Study
